The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with Paclitaxel
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070 · cited 1×
“Angiogenic endothelial cells may be considered as a major target for therapeutic intervention because they are easily accessible [7,8].”
BackgroundTumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565 · cited 1×
“The combination of leaky vasculature and poor lymphatic drainage results in the well-known Enhanced Permeability and Retention (EPR) effect [4].”
BackgroundNanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233 · cited 1×
“Efforts are now focused on attempts to kill cancer cells by more specific targeting while sparing normal cells [1–3].”
BackgroundPromotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600
Requirement of Vascular Integrin α v β 3 for Angiogenesis
Brooks, P. C., Clark, R. A. F., & Cheresh, D. A. (1994) · Science · doi:10.1126/science.7512751 · Cited by 3,020
RGD modified polymers: biomaterials for stimulated cell adhesion and beyond
Hersel, U., Dahmen, C., & Kessler, H. (2003) · Biomaterials · doi:10.1016/s0142-9612(03)00343-0 · Cited by 2,582
Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model
Arap, W., Pasqualini, R., & Ruoslahti, E. (1998) · Science · doi:10.1126/science.279.5349.377 · Cited by 2,054
Active targeting schemes for nanoparticle systems in cancer therapeutics
Byrne, J. D., Betancourt, T., & Brannon-Peppas, L. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.08.005 · Cited by 1,731
Ligand-targeted therapeutics in anticancer therapy
Allen, T. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc903 · Cited by 1,647
Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach
des Rieux, A., Fievez, V., Garinot, M., Schneider, Y.-J., & Préat, V. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.08.013 · Cited by 1,305
Hypersensitivity reactions from taxol.
Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L., Baker, J. R., Van Echo, D. A., Von Hoff, D. D., & Leyland-Jones, B. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1263 · Cited by 1,174
Paclitaxel and its formulations
Singla, A. K., Garg, A., & Aggarwal, D. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(01)00986-3 · Cited by 1,100
Nanoparticles for drug delivery in cancer treatment
Haley, B., & Frenkel, E. (2008) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.03.015 · Cited by 791
Fonseca, C., Simões, S., & Gaspar, R. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00212-2 · Cited by 755
Specialization of tumour vasculature
Ruoslahti, E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc724 · Cited by 722
Paclitaxel-loaded PEGylated PLGA-based nanoparticles: In vitro and in vivo evaluation
Danhier, F., Lecouturier, N., Vroman, B., Jérôme, C., Marchand-Brynaert, J., Feron, O., & Préat, V. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.09.086 · Cited by 616
Self-citationRecent advances in the synthesis of aliphatic polyesters by ring-opening polymerization☆
JEROME, C., & LECOMTE, P. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.02.008 · Cited by 590 · cited 1×
“The composition and molecular weights of polymers synthesized by conventional ring-opening polymerization processes [37] and used in the formulations are summarized in Table 1.”
MethodSelf-citationA reevaluation of integrins as regulators of angiogenesis
Hynes, R. O. (2002) · Nature Medicine · doi:10.1038/nm0902-918 · Cited by 548
Temming, K., Schiffelers, R. M., Molema, G., & Kok, R. J. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.10.002 · Cited by 467
Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis
Murphy, E. A., Majeti, B. K., Barnes, L. A., Makale, M., Weis, S. M., Lutu-Fuga, K., Wrasidlo, W., & Cheresh, D. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803728105 · Cited by 455
In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin–PLGA conjugates
Yoo, H. S., Lee, K. H., Oh, J. E., & Park, T. G. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00280-7 · Cited by 374
Roberts, M., Barry, S., Woods, A., van der Sluijs, P., & Norman, J. (2001) · Current Biology · doi:10.1016/s0960-9822(01)00442-0 · Cited by 348
PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination
Garinot, M., Fiévez, V., Pourcelle, V., Stoffelbach, F., des Rieux, A., Plapied, L., Theate, I., Freichels, H., Jérôme, C., Marchand-Brynaert, J., et al. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.04.021 · Cited by 331
Self-citationGriffioen, A., Damen, C., Blijham, G., & Groenewegen, G. (1996) · Blood · doi:10.1182/blood.v88.2.667.bloodjournal882667 · Cited by 304
Meyer, A., Auernheimer, J., Modlinger, A., & Kessler, H. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206777947740 · Cited by 291
Regulation of vascular cell adhesion molecule 1 on human dermal microvascular endothelial cells
Swerlick, R. A., Lee, K. H., Li, L. J., Sepp, N. T., Caughman, S. W., & Lawley, T. J. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.2.698 · Cited by 264
Polymers and nanoparticles: Intelligent tools for intracellular targeting?
Breunig, M., Bauer, S., & Goepferich, A. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2007.06.010 · Cited by 215
Xiong, X.-B., Huang, Y., Lu, W.-L., Zhang, X., Zhang, H., Nagai, T., & Zhang, Q. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.03.030 · Cited by 205
Park, J. H., Kwon, S., Nam, J.-O., Park, R.-W., Chung, H., Seo, S. B., Kim, I.-S., Kwon, I. C., & Jeong, S. Y. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2003.12.020 · Cited by 190
Zweers, M. L. T., Engbers, G. H. M., Grijpma, D. W., & Feijen, J. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.09.008 · Cited by 162
Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination
Fievez, V., Plapied, L., des Rieux, A., Pourcelle, V., Freichels, H., Wascotte, V., Vanderhaeghen, M.-L., Jerôme, C., Vanderplasschen, A., Marchand-Brynaert, J., et al. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2009.04.009 · Cited by 158
Self-citationIdentification of the αvβ3 Integrin-interacting Motif of βig-h3 and Its Anti-angiogenic Effect
Nam, J.-O., Kim, J., Jeong, H.-W., Lee, S.-J., Lee, B.-H., Choi, J., Park, R., Park, J. Y., & Kim, I.-S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300358200 · Cited by 126
Rational Design of Highly Active and Selective Ligands for the α5β1 Integrin Receptor
Heckmann, D., Meyer, A., Laufer, B., Zahn, G., Stragies, R., & Kessler, H. (2008) · ChemBioChem · doi:10.1002/cbic.200800045 · Cited by 89
Multivalent RGD synthetic peptides as potent α V β 3 integrin ligands
Garanger, É., Boturyn, D., Coll, J., Favrot, M., & Dumy, P. (2006) · Organic & Biomolecular Chemistry · doi:10.1039/b517706e · Cited by 89
Hu, Z., Luo, F., Pan, Y., Hou, C., Ren, L., Chen, J., Wang, J., & Zhang, Y. (2007) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.31615 · Cited by 82
Schraa, A. J., Kok, R. J., Berendsen, A. D., Moorlag, H. E., Bos, E. J., Meijer, D. K. F., de Leij, L. F. M. H., & Molema, G. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00206-7 · Cited by 63
Cao, L., Wang, H., Li, J., & Zhang, H. (2004) · Journal of Chromatography A · doi:10.1016/j.chroma.2004.11.093 · Cited by 61
Rieux, A. D., Fiévez, V., Momtaz, M., Detrembleur, C., Alonso, M. J., van Gelder, J., Cauvin, A. J., Schneider, Y., & Véronique Préat, A. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.12.023 · Cited by 58
PCL−PEG-Based Nanoparticles Grafted with GRGDS Peptide: Preparation and Surface Analysis by XPS
Pourcelle, V., Devouge, S., Garinot, M., Véronique Préat, A., & Marchand‐Brynaert, J. (2007) · Biomacromolecules · doi:10.1021/bm700841y · Cited by 57
Self-citationCell adhesive PET membranes by surface grafting of RGD peptidomimetics
Biltresse, S., Attolini, M. M., & Marchand‐Brynaert, J. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2004.11.042 · Cited by 55
Self-citationJordan, B. F., Sonveaux, P., Féron, O., Grégoire, V., Beghein, N., & Gallez, B. (2003) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)04505-4 · Cited by 46
Pourcelle, V., Freichels, H., Stoffelbach, F., Auzély‐Velty, R., Jérôme, C., & Marchand‐Brynaert, J. (2009) · Biomacromolecules · doi:10.1021/bm900027r · Cited by 45
Self-citationThe role of integrin α5β1 in the regulation of corneal neovascularization
Muether, P. S., Dell, S., Kociok, N., Zahn, G., Stragies, R., Vossmeyer, D., & Joussen, A. M. (2007) · Experimental Eye Research · doi:10.1016/j.exer.2007.06.004 · Cited by 44
Hall, H., Djonov, V., Ehrbar, M., Hoechli, M., & Hubbell, J. A. (2004) · Angiogenesis · doi:10.1007/s10456-004-1328-5 · Cited by 41
Biltresse, S., Attolini, M. M., Dive, G., Cordi, A. A., Tucker, G. C., & Marchand‐Brynaert, J. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.07.055 · Cited by 30
Self-citationLöhbach, C., Neumann, D., Lehr, C., & Lamprecht, A. (2006) · Journal of Nanoscience and Nanotechnology · doi:10.1166/jnn.2006.476 · Cited by 18
Cited by
PLGA-based nanoparticles: An overview of biomedical applications
Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.043 · Cited by 3,806
Self-citationStrategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
Danhier, F., Feron, O., & Préat, V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.027 · Cited by 2,800
Self-citationBiomedical applications of biodegradable polymers
Ulery, B. D., Nair, L. S., & Laurencin, C. T. (2011) · Journal of Polymer Science Part B: Polymer Physics · doi:10.1002/polb.22259 · Cited by 2,206
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Metadata
- Authors
- Danhier, F., Vroman, B., Lecouturier, N., Crokart, N., Pourcelle, V., Freichels, H., Jérôme, C., Marchand-Brynaert, J., Feron, O., & Préat, V.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2009-12
- Volume
- 140
- Issue
- 2
- Pages
- 166-173
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2065302847
- Cited by
- 335
- References
- 46
- FWCI
- 10.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.